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Abstract
Introduction: Anti-estrogen therapy has been shown to reduce mammographic breast density (MD). We
hypothesized that a short-term change in breast density may be a surrogate biomarker predicting response to
adjuvant endocrine therapy (ET) in breast cancer.
Methods: We analyzed data for 1,065 estrogen receptor (ER)-positive breast cancer patients who underwent
surgery between 2003 and 2006 and received at least 2 years of ET, including tamoxifen and aromatase inhibitors.
MD was measured using Cumulus software 4.0 and expressed as a percentage. MD reduction (MDR) was defined
as the absolute difference in MD of mammograms taken preoperatively and 8-20 months after the start of ET.
Results: At a median follow-up of 68.8 months, the overall breast cancer recurrence rate was 7.5% (80/1065). Mean
MDR was 5.9% (range, -17.2% to 36.9%). Logistic regression analysis showed that age < 50 years, high preoperative
MD, and long interval between start of ET to follow-up mammogram were significantly associated with larger MDR
(p < 0.05). In a survival analysis, tumor size, lymph node positivity, high Ki-67 (≥ 10%), and low MDR were
independent factors significantly associated with recurrence-free survival (p < 0.05). Compared with the group
showing the greatest MDR (≥ 10%), the hazard ratios for MDRs of 5-10%, 0-5%, and < 0% were 1.33, 1.92, and 2.26,
respectively.
Conclusions: MD change during short-term use of adjuvant ET was a significant predictor of long-term recurrence
in women with ER-positive breast cancer. Effective treatment strategies are urgently needed in patients with low
MDR despite about 1 year of ET.
Introduction
Adjuvant endocrine therapy is the most effective systemic
treatment modality for patients with hormone receptor
(ER)-positive breast cancer, although many patients
experience tumor recurrence during or after completion
of endocrine therapy. Identifying factors that can predict
disease recurrence early during adjuvant treatment may
result in a more tailored strategy for patients likely to be
endocrine resistant and may improve their overall
outcomes.
Mammographic breast density (MD) is defined by the
relative proportion of radiopaque areas, indicating the
presence of fibroglandular tissue among the surrounding
fatty component of the breast. High MD is associated
with increased risk of breast cancer in both Western
and Asian women [1,2]. The degree of lobular involu-
tion is known to have inverse correlation with breast
cancer risk as well [3].
Studies on the efficacy of tamoxifen for chemopreven-
tion of breast cancer in high-risk women have shown that
MD is decreased following tamoxifen treatment [4,5].
Moreover, 12- to 18-month change in MD was found to
be an excellent predictor of response to tamoxifen in the
preventive setting [5]. However, no studies to date have
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addressed the association between MD reduction and the
efficacy of adjuvant endocrine treatment in breast cancer
patients. Using quantitative imaging analysis software to
assess serial changes in MD, we investigated the associa-
tion between the degree of MD reduction and long-term
breast cancer recurrence in ER-positive breast cancer
patients who received adjuvant endocrine therapy.
Materials and methods
Study population
Using our institution’s prospectively maintained web-
based database, we identified a total of 1,542 ER-positive
breast cancer patients who underwent curative surgery at
Seoul National University Hospital between October 2003
and December 2006. Patients were excluded if: 1) they did
not receive adjuvant endocrine treatment, such as tamoxi-
fen or an aromatase inhibitor, or were treated for less than
2 years; 2) their digital mammogram images were not
available; 3) they had bilateral breast cancer, or 4) distant
metastasis was observed before the start of endocrine ther-
apy. Clinical and pathologic information on the 1,065 sub-
jects was obtained from the database and used for further
analysis. Treatment with adjuvant chemotherapy and/or
radiotherapy was generally decided according to the insti-
tution’s guidelines. The standard duration of treatment
with tamoxifen is 5 years. Postmenopausal women were
treated with the aromatase inhibitors anastrozole and
letrozole for up to 5 years after surgery or after 2 to
3 years of tamoxifen.
Mammographic density measurement
MD was quantitatively measured on cranio-caudal (CC)
images of the unaffected breast using Cumulus software
4.0 (University of Toronto, Toronto, Canada) by a single
investigator (JK) blinded to treatment outcome. All evalu-
ated images were digital mammograms performed at our
institution, so film scanning was unnecessary. Mammo-
graphic density reduction (MDR) was based on two digital
mammograms; the first was taken within 2 weeks pre-
surgery (preMD), and the second 8 to 20 months after the
start of adjuvant endocrine treatment (postMD), and
defined as the absolute difference between the MD of
these two images (% MDR = % preMD - % postMD). The
MD reduction ratio (MDRR) was also calculated (%
MDRR = (preMD -postMD) × 100/preMD). Intraobserver
reproducibility, tested for 10% of randomly selected
images (213/2,130), was 0.93 (Pearson correlation
coefficient).
Statistical analysis
Change in MD was categorized into four levels, an increase
(MDR < 0), 0 ≤ MDR < 5%, 5 ≤ MDR < 10%, and MDR ≥
10%, and into a binary variable (MDR ≥ 5% and < 5%),
with the 5% and 10% absolute reduction cut-offs based on
previous findings [5]. We also analyzed absolute MDR as a
continuous variable. The chi-square test and t-test were
used to compare factors that could affect change in MD.
All loco-regional or distant disease recurrences were
regarded as recurrence events in recurrence-free survival
analysis. Survival curves were estimated by the Kaplan-
Meier method and compared using the log-rank test. Mul-
tivariate analyses were conducted using Cox’s proportional
hazard regression model. All statistical analyses were per-
formed using SPSS (version 17.0) software package (Chi-
cago, IL, USA) and factors with P < 0.05 were considered
statistically significant. Written informed consent was
taken prior to surgery in all patients and the study proto-
col including the use of the database was approved by the
Institutional Review Board of Seoul National University
Hospital and met the guidelines of the responsible govern-
mental agencies.
Results
Demographics and result of mammographic density
measurement
The mean age of the 1,065 included patients was 49.1
years (range, 24 to 77 years) (Table 1), and their mean
duration of overall endocrine therapy was 5.1 years (range,
0.9 to 7.9 years). One hundred and twenty-seven patients
(11.9%) had ductal carcinoma in situ (DCIS). Second
mammograms used for density measurements were taken
an average 13.1 months (range, 8 to 20 months) after the
start of endocrine therapy. The result of MD measure-
ments (preMD, postMD, MDR, and MDRR) are shown in
Table 2. Mean MDR was 5.9% (range, -17.2% to 36.9%).
Factors associated with density change
Patients were dichotomized by degree of MD reduction
using a cut-off of 5% (MDR ≥ 5% vs. < 5%), and factors in
the two groups were compared to identify associations
with high MDR. Patients with MDR ≥ 5% were signifi-
cantly younger (46.5 ± 8.0 vs. 51.9 ± 9.8 years, P < 0.001;
Additional file 1, Table S1) and were significantly more
likely to have been treated with tamoxifen than with an
aromatase inhibitor (P < 0.001). Similarly, when MDR was
analyzed as a continuous variable, mean MDR was higher
in patients who received tamoxifen than in those who
received an aromatase inhibitor (6.5 ± 7.1 vs. 3.1 ± 6.3%, P
< 0.001, data not shown). Mean time from start of endo-
crine therapy to the second mammogram was longer in
the group with MDR ≥ 5% than in the group with MDR <
5% (13.5 ± 3.1 vs. 12.6 ± 3.2 months, P < 0.001). Moreover,
mean preMD was higher with MDR ≥ 5% than with MDR
< 5% (40.9 ± 12.4% vs. 30.0 ± 13.3%, P < 0.001).
Multivariate logistic regression analysis was performed
to identify factors independently associated with high
MDR (Table 3). We found that age < 50 years, high pre-
operative MD, and long interval between start of
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endocrine therapy and the second mammogram were
significantly associated with high MDR (P < 0.05). The
data were consistently significant on stepwise regression
analysis when adjusted by age, preMD and ET regimen
(Additional file 1, Table S2).
Density change and recurrence-free survival
During a median follow-up of 67.7 months, 80 of the
1,065 patients (7.5%) experienced tumor recurrence
(Table 1). Multivariate Cox regression analysis showed
that when analyzed as a continuous variable, MDR was
Table 1 Patient demographics
Variable Mean ± SD (range) Number %
Age, yr 49.0 ± 9.3 (24-77)
≤ 50 680 63.8
> 50 385 36.2
Duration of ET, yr 5.0 ± 1.0 (0.9-7.9)
ET regimen
Tamoxifen 5 yr 657 61.7
Tamoxifen 2-3 yr - > AI (total 5 yr) yr 41 3.8
Tamoxifen 5 yr - > AI 192 18
AI 5 yr 16.4
Tumor size (cm) 2.1 ± 1.4 (0.1-10.0)
≤ 2 cm 638 59.9
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Contralateral breast 8 10
Distant metastasis 51 63.8
Clinicopathological factors of the 1065 patients. ET: endocrine therapy; AI: aromatase inhibitor; HER2: Human Epidermal Growth Factor Receptor 2.
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significantly associated with recurrence-free survival
(hazard ratio (HR) = 0.95, 95% confidence interval (CI)
0.92 to 0.99, P = 0.005, Additional file 1, Table S3).
When these patients were categorized into four groups
according to the degree of MD change (the reference
group with MDR ≥ 10%, plus three groups with MDR of
5 to 10%, 0 to 5%, and < 0% respectively), the HR for
recurrence was proportional to the decrease in MDR.
Compared with the reference group with the greatest
MDR reduction (≥ 10%), the HRs for 5 to 10%, 0 to 5%,
and < 0% MDR were 1.33 (P = 0.413), 1.92 (P = 0.048),
and 2.26 (P = 0.027), respectively (Table 4, Figure 1A).
Large tumor size, lymph node metastasis, and high Ki-
67 level (≥ 10%) were also significantly associated with
recurrence-free survival. The risk of recurrence was 1.67
times higher with a lower MDR of < 5% compared to
MDR ≥ 5% when adjusted for age and preMD by for-
ward selection stepwise analysis (HR 1.67, 95% CI 1.07
to 2.62, P = 0.025) (Additional file 1, Table S4).
HRs for recurrence according to dichotomized MDR
(≥ 5% vs. < 5%) in various subgroups are shown in a for-
est plot (Figure 2). Subgroup analysis showed that the
association between low MDR and high risk of recur-
rence differed by age group (> 50 vs. ≤ 50 years), with
MDR significantly associated with risk of recurrence only
in the postmenopausal group. MDR also significantly
predicted recurrence in patients taking AIs, and was
strongly correlated with the factor of age. When adjusted
by age and ET regimen the findings were consistent,
showing low MDR as a significant risk factor for recur-
rence in patients who had undergone chemotherapy (HR
1.70, 95% CI 1.04 to 2.77, P = 0.033).
We also calculated the MDRR in this group of
patients. We found that MDRR was significantly asso-
ciated with risk of recurrence when analyzed as a con-
tinuous and as a binary variable. Compared with
patients with MDRR ≥ 25%, the HRs for recurrence for
patients with MDRR of 0 to 10% and MDRR < 0% were
2.09 and 2.17, respectively (P < 0.05 each; Table 5,
Figure 1B). After adjusting for confounding factors,
patients with MDRR ≥ 15% had a higher risk of recur-
rence than patients with MDRR < 15% (HR 1.60, 95%
CI 1.02 to 2.50, P = 0.041) (Additional file 1, Table S5).
Discussion
We have shown here that short-term MDR is predictive
of long-term outcomes following endocrine therapy in
patients with ER-positive breast cancer. Patients who
experienced < 5% absolute MDR and those with
increased MD after about 1 year of endocrine therapy
were at 1.92- and 2.26-fold greater risk of recurrence
Table 2 Distribution of mammographic density before
and after treatment and change in mammographic
density
Variable Mean (range) Number %
PreMD, %* 35.77 ± 13.94 (5.42-82.18)
< 10% 26 2.4
10% - 25% 223 20.9
25% - 50% 641 60.2
≥ 50% 175 16.4
PostMD, % 29.84 ± 12.12 (3.90-72.31)
< 10% 35 3.3
10% - 25% 364 34.2
25% - 50% 611 57.4
≥ 50% 55 5.2
MDR, % 5.92 ± 7.08 (-17.2-36.9)
< 5% 505 47.4
≥ 5% 560 52.6
< 0% (increased) 190 17.8
0%-5% 314 29.5
5%-10% 276 25.9
≥ 10% 285 26.8
MDRR, %
< 15% 486 45.6
≥ 15% 579 54.4
< 0% (increased) 190 17.8
0%-10% 198 18.6
10%-25% 356 33.4
≥ 25% 321 30.1
Mammographic density reduction (MDR) and MDR ratio (MDRR) ((preMD -
postMD) × 100/preMD) were initially evaluated as continuous variables then
as dichotomized, quartered variables. Patients were divided into two groups
(MDR < 5%, 5% ≤ MDR), and four groups (MDR ≥ 10%, 5% ≤ MDR < 10%, 0 ≤
MDR < 5%, and MDR < 0% (increased MD)). PreMD: initial preoperative
mammographic density; PostMD: density of follow up mammography after 8
to 20 months of hormone therapy.
Table 3 Factors associated with mammographic density reduction (MDR)
Variable Odds ratio 95% Confidence interval P-value
Age ≤ 50 yr 1.84 1.30, 2.61 0.001
Interval to follow-up mammography, months* 1.07 1.02, 1.12 0.006
Initial tamoxifen (vs. AI) 0.99 0.65, 1.51 0.958
PreMD, % 1.06 1.04, 1.07 < 0.001
Adjuvant chemotherapy 1.41 1.00, 2.00 0.052
Factors associated with mammographic density reduction (MDR). Odds ratios are shown for each factor having MDR < 5% (multivariate logistic regression
analysis). *Interval between start of endocrine therapy and follow-up mammography. AI: aromatase inhibitor; PreMD: preoperative mammographic density.
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respectively, than patients with MDR ≥ 10%. This asso-
ciation was also observed when absolute MDR was ana-
lyzed as a continuous variable, and when MDRR rather
than absolute MDR was assessed.
Regardless of the evolution of anti-estrogen therapy, a
substantial proportion of patients with ER-positive
breast cancer experience disease recurrence during fol-
low-up. Effective biomarkers are needed to predict
endocrine resistance despite ER expression. Many pre-
vious investigations have focused on tumor factors asso-
ciated with endocrine resistance [6,7]. The level of MDR
resulting from endocrine treatment is a host factor indi-
cating individual susceptibility to endocrine agents.
These findings support the hypothesis that host
response to adjuvant endocrine therapy may be as
important and should be considered in addition to the
clinicopathological characteristics of the primary tumor.
Breast density is one of the strongest risk factors for
breast cancer development [8]. A recent study showed
that the magnitude of the association of exogenous or
endogenous hormone exposure and mammographic
density change is related to future risk of breast cancer
[9]. Cuzick et al. conducted a nested case-control study
within the IBIS-I study, a randomized prevention trial of
tamoxifen versus placebo to determine the association
between tamoxifen-induced density change and breast
cancer risk. They showed that the 12- to 18-month
change in mammographic breast density is an excellent
predictor of tamoxifen efficacy in the preventive setting
[5].
Our findings raise the question of whether treatment
strategy should be altered based on change in MD after
only one year of endocrine therapy. For the clinical
application of individualized therapy, studies are needed
Table 4 Predictive impact of mammographic density reduction (MDR) on recurrence-free survival
Variable Hazard ratio 95% Confidence interval P-value
Age, yr (continuous) 0.99 0.96, 1.02 0.393
MDR
≥ 10% (reference) 1.00 0.101
5-10% 1.33 0.67, 2.65 0.413
0-5% 1.92 1.01, 3.64 0.048
< 0% (increased) 2.26 1.10, 4.64 0.027
Size, cm (continuous) 1.19 1.05, 1.35 0.006
Lymph node positive 2.02 1.20, 3.40 0.008
High histologic grade 1.29 0.78, 2.16 0.323
Chemotherapy 0.79 0.39, 1.60 0.520
Ki-67 ≥ 10% 1.77 1.05, 3.00 0.033
Cox proportional hazard regression model for recurrence-free survival. Risk of recurrence was analyzed using the group with the greatest reduction (MDR ≥ 10%)












































































Figure 1 Recurrence-free survival stratified by density reduction group. (A) Recurrence-free survival according to mammographic density
reduction (MDR). Patients were divided into four groups, MDR ≥ 10%, 5% ≤ MDR < 10%, 0 ≤ MDR < 5%, and MDR < 0% (increased MD). (B)
Recurrence-free survival according to mammographic density reduction ratio (MDRR). Patients were divided into four groups, MDRR ≥ 25%, 10%
≤ MDRR < 25%, 0 ≤ MDRR < 10%, and MDRR < 0% (increased MDRR). Survival curves represent the results of Cox proportional hazard models
adjusted for age, tumor size, lymph node, histologic grade, adjuvant chemotherapy, and Ki-67 status.
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to evaluate the ability of shorter-term changes in MD,
such as after < 6 months, to predict risk of recurrence,
and new treatment strategies also should be tested
according to the predicted result.
We also found that factors such as age < 50 years,
high preoperative MD, and long interval between the
start of endocrine therapy and the second mammogram
were significantly associated with high MDR, indicating
that a dense breast per se is not a sign of endocrine
resistance, and that MD decreases more with prolonged
endocrine treatment.
Although MDR was greater in patients < 50 years of
age than in those aged ≥ 50 years, the degree of MDR
was not associated with recurrence in younger patients.
The reason for this is not clear, although it may be due
to the complicated hormonal milieu and factors other
than endocrine therapy affecting breast density in
younger women. The relatively small number of events
in patients aged < 50 years (43/680, 7.1%) in our dataset
could have affected the statistical significance and
further evaluation within a larger dataset is required.
The degree of MDR may differ according to the type
of endocrine therapy. Tamoxifen was reported to be
associated with an 8% mean absolute reduction in breast
density at 1.5 years and a reduction of 14% after 4.5
years [10,11]. Raloxifene has been reported to decrease
absolute breast density by 1.5% per year [12]. In a small
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Figure 2 Subgroup analysis of association between mammographic density reduction (MDR) and disease recurrence. Forest plot shows
hazard ratios (HRs) for recurrence in patients with MDR < 5% vs. those with MDR ≥ 5% in the different patient subgroups.
Table 5 Predictive impact of mammographic density reduction ratio (MDRR) on recurrence-free survival
Variable Hazard ratio 95% Confidence interval P-value
Age, yr (continuous) 0.99 0.97-1.02 0.600
MDRR (%)*
≥ 25% 1.00 Referent 0.078
10%-25% 1.37 0.73-2.58 0.327
0%-10% 2.09 1.07-4.06 0.030
< 0% (increased) 2.17 1.08-4.35 0.030
Size, cm (continuous) 1.19 1.05-1.35 0.007
Lymph node positive 1.98 1.18-3.34 0.010
High histologic grade 1.34 0.80-2.24 0.261
Chemotherapy done 0.79 0.39-1.60 0.519
Ki-67 ≥ 10% 0.60 0.33-0.94 0.029
Cox proportional hazard regression model for recurrence-free survival. Risk of recurrence was analyzed using the group with the greatest reduction (MDRR ≥
25%) as the reference. *MDRR = (pre-treatment MD - post-treatment MD) × 100/pre-treatment MD.
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effect on breast density in the contralateral breast after 6
months and resulted in a 16% relative reduction (P =
0.08) after 12 months [13]. Letrozole and exemestane
also did not reduce mammographic breast density [14].
Addition of an aromatase inhibitor to hormone replace-
ment therapy resulted in a significant reduction in
breast density [1]. In a univariate analysis we found that
tamoxifen treatment was associated with a higher MDR
than treatment with aromatase inhibitors (P < 0.001).
However, an association between MDR and recurrence-
free survival was observed in our aromatase inhibitor
group.
There is no definite evidence-based mechanism for an
association between anti-estrogen therapy, reduced
breast density and a better outcome. With aromatase
inhibitors, it is possible that reduced density reflects
effective circulating estrogen deprivation, and as a result,
also affects micro-metastases. Another explanation is the
difference in the drug metabolism efficiency of the host.
Patients with adequate serum drug concentrations
should have a better response and outcome. However,
the metabolic mechanism of tamoxifen and aromatase
inhibitors must be different. Adherence to a prescribed
drug can partly explain the correlation between density
change and patient outcome. In premenopausal and
perimenopausal women, a good chemotherapy response
could cause chemotherapy-induced ovarian failure, and
as a result, could reduce breast density and improve dis-
ease-free survival. It is unknown, but is less likely that
tumor-associated fibroblasts or other stromal cells in
the breast might directly affect distant micro-metastatic
cancer cells.
We also found that 17.8% of our study subjects had
increased MD after endocrine therapy. Similarly, in the
preventive tamoxifen study IBIS-1, 11% of patients trea-
ted with tamoxifen and 24% given placebo had an
increased MD. The mechanism of this increase in MD
is unknown. Investigations are needed to determine
whether in these women, tamoxifen acts as an estrogen
agonist in the breast.
The reproducibility of MD measurement is important,
and studies indicate good intraobserver reproducibility
with correlation coefficients of 0.92 to 0.96 [15]. We
used Cumulus software, which has been the most widely
used for MD measurements in previous studies. Using
digital mammographic images, we found that the Pear-
son correlation coefficient was 0.93.
The major limitation of the study was the absence of
data on factors that may be closely associated with
breast density, such as body mass index. Because this
study was retrospective in design, the timing of follow-
up mammography was not uniform, varying from 8 to
20 months after initiation of endocrine therapy. Another
limitation was that the study subjects received
heterogeneous adjuvant therapy regimens. We also
could not determine the degree of ER expression in
tumors, a potential major factor affecting resistance to
endocrine treatment.
To our knowledge, this study was the first to assess
the value of MD change as a predictive surrogate in
breast cancer patients receiving adjuvant endocrine ther-
apy. The positive result we obtained warrants larger-
scale prospective studies. Basic research to identify the
molecular pathways related to endocrine resistance and
mammographic density is also needed.
Conclusion
In conclusion, low MDR or increased MD during short-
term endocrine therapy was independently associated
with poor recurrence-free survival in patients with ER-
positive breast cancer. Change in MD may be predictive
of response to adjuvant endocrine therapy. Studies
should be designed to investigate how to use this valu-
able information in routine clinical practice.
Additional material
Additional file 1: Table S1: Univariate analysis for mammographic
density reduction (MDR). Analysis of factors associated with MDR
divided into two group (MDR < 5% vs. MDR ≥ 5%). Younger age,
tamoxifen use, longer interval from initial endocrine therapy, higher
PreMD, adjuvant chemotherapy were likely to have higher MDR (≥ 5%).
Table S2: Stepwise regression analysis (forward selection) of factors for
MDR* ≥ 5%. After adjusting for the confounding factors, age, interval to
follow up, and preoperative mammographic density, adjuvant
chemotherapy was not independently associated with MDR. Table S3:
Cox proportional analysis for recurrence-free survival (RFS): MDR as a
continuous variable. MDR analyzed as a continuous variable was an
independent risk factor for recurrence, along with size, lymph node (LN)
status, and Ki-67 level. Table S4: Cox proportional hazard regression
(forward selection) analysis for RFS. After adjusting for confounding
factors, patients with MDR < 5% had 1.67 times significantly higher risk
of recurrence than the MDR ≥ 5% group. Tumor size, lymph node (LN)
positivity, and Ki-67 (cut-off 10%) were independent prognostic factors as
known. Table S5: Cox proportional hazard regression (forward selection)
analysis for RFS. After adjusting for confounding factors, patients with
MDRR < 15% had 1.60 times significantly higher risk of recurrence than
the MDRR ≥ 15% group (P = 0.041). Tumor size, lymph node (LN)
positivity, and Ki-67 (cut-off 10%) were independent prognostic factors as
known.
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